文献速递造血干细胞移植与细胞治疗

芦可替尼联合依那西普快速缓解异基因干细胞移植后激素难治性重度急性移植物抗宿主病:多中心前瞻性研究结果

Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.
PubMed 文献 · Am J Hematol · 2020-07-06

该多中心前瞻性研究纳入64例异基因造血干细胞移植后III-IV级激素难治性急性移植物抗宿主病患者,评估芦可替尼联合依那西普的疗效与安全性。联合治疗第28天总缓解率为87.5%(95%CI 79.7%-95.3%),其中73.4%达完全缓解;2年总生存率为61.2%。作者认为该联合方案对重度aGVHD非常有效且相对安全,但各类感染并发症值得更多关注。

要点

  • 联合治疗第28天总缓解率87.5%,其中73.4%达完全缓解。
  • 第28天75.4%患者每日糖皮质激素剂量减少≥75%。
  • 3/4级贫血、白细胞减少、血小板减少及CMV再激活分别见于29.7%、26.6%、39.1%、50.0%患者。

核心结论

  • 芦可替尼联合依那西普对重度aGVHD患者非常有效且相对安全,但各类感染并发症值得更多关注。

研究设计与样本

  • 多中心前瞻性研究,纳入64例异基因造血干细胞移植后III-IV级激素难治性急性移植物抗宿主病患者,评估芦可替尼联合依那西普的疗效与安全性,研究注册于中国临床试验注册中心(ChiCTR1900024408)。

主要发现

  • 联合治疗第28天总缓解率为87.5%(95%CI 79.7%-95.3%),其中73.4%达完全缓解(CR)。
  • 第28天75.4%患者每日糖皮质激素剂量减少≥75%。
  • 从aGVHD至开始芦可替尼时间延迟(OR=4.88,95%CI 0.98-23.56)、3-4级肝脏aGVHD(OR=8.57,95%CI 0.96-46.59)及肠道肠杆菌科细菌定植(OR=12.39,95%CI 1.71-59.77)与未完全缓解相关。
  • 3/4级贫血、白细胞减少、血小板减少及CMV再激活分别见于29.7%、26.6%、39.1%和50.0%的患者。
  • 25例(39.1%)发生≥3级严重感染并发症,其中肺部感染最常见(15/64,23.4%);联合治疗后2年总生存率为61.2%,2年非复发死亡率和原发恶性肿瘤复发率分别为26.7%和15.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

About half of patients with severe acute graft vs host disease (aGVHD) show resistance to treatment with first-line steroids. We enrolled 64 patients with grades III-IV SR-aGVHD after allogeneic hematopoietic stem cell transplantation (allo-SCT), to assess the efficacy and safety of the combination therapy of ruxolitinib and etanercept. The overall response rate was 87.5% (95% CI, 79.7%-95.3%) at day 28 of the combination treatment, from which 73.4% reached complete response (CR). A marked reduction ≥75% in daily corticosteroid dosing was documented in 75.4% of patients at day 28. Delayed time from aGVHD to ruxolitinib (OR = 4.88, 95% CI, 0.98-23.56), stages 3-4 liver aGVHD (OR = 8.57, 95% CI, 0.96-46.59) and gut Enterobacteriaceae colonization (OR = 12.39, 95% CI, 1.71-59.77) were related to incomplete response. Grades 3/4 anemia, leukopenia, or thrombocytopenia and CMV-reactivation were found in 29.7%, 26.6%, 39.1%, and 50.0% of patients, respectively. So, 25 (39.1%) experienced complications of severe infection ≥3 grade, in which pulmonary infections were most frequent (15/64, 23.4%). The 2-year overall survival (OS) after the combination therapy was 61.2%. The 2-year incidence of non-relapse mortality and relapse of the underlying malignancy was 26.7% and 15.7%, respectively. Combined treatment with ruxolitinib and etanercept was very effective and relatively safe for severe aGVHD patients, while the various infection complications deserve more attention. This study was registered at the Chinese Clinical Trial Registry (ChiCTR1900024408).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wu H, Shi J, et al. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study. Am J Hematol. 2020. PMID: 32510625. doi:10.1002/ajh.25898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。